TrxR1 is also an established anti-cancer drug target (Wang et al., 2012), and increased TrxR1 production or activity provides chemotherapeutic resistance to treatments that rely on the production of ROS to kill cells (Roh et al., 2017). The gene discussed is TXNRD1; the disease is cancer.